SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia

Masahiro Sugano, Keiko Tsuchida, Toyoki Maeda, Naoki Makino

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Vascular endothelial growth factor (VEGF) receptor-2 (KDR/flk-1) has a tyrosine kinase domain, and once activated, induces the autophosphorylation of the tyrosine residues, which is essential for angiogenesis. SHP-1, a cytoplasmic protein tyrosine phosphatase, plays a negative regulatory role in signal transduction pathways by dephosphorylation of the receptors to which it binds. Thus, therapeutic angiogenesis designed to inhibit expression of SHP-1 would be beneficial in hindlimb ischemia. In in vitro, the inhibition of SHP-1 by SHP-1 siRNA impaired the ability of TNF to block the tyrosine phosphorylation of KDR/flk-1 induced by VEGF and showed an increase in endothelial cell growth. In in vivo, SHP-1 mRNA, SHP-1 protein levels and VEGF were increased in a rat model of hindlimb ischemia. Upon injection to the ischemic adductor muscle, vector-based siRNA reduced SHP-1, increased phosphorylation of KDR/flk-1, and markedly increased capillary density. Our data demonstrated in vivo the potential use of siRNA targeting SHP-1 as therapy for peripheral ischemic diseases.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
Issue number1
Publication statusPublished - Mar 2007

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia'. Together they form a unique fingerprint.

Cite this